The stock of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) is a huge mover today! About 29.59 million shares traded hands or 2772.82% up from the average. ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) has risen 83.18% since March 14, 2016 and is uptrending. It has outperformed by 77.57% the S&P500.
The move comes after 9 months positive chart setup for the $177.85M company. It was reported on Oct, 17 by Barchart.com. We have $6.12 PT which if reached, will make NASDAQ:CTRV worth $295.23 million more.
According to Zacks Investment Research, “ContraVir Pharmaceuticals Inc. is a biopharmaceutical company. The company is involved in the discovery and development of antiviral therapies. ContraVir Pharmaceuticals Inc. is headquartered in Edison, New Jersey.”
More recent ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) news were published by: 247Wallst.com which released: “How ContraVir Pharma Won Big on Its HBV Interim Results” on October 13, 2016. Also Prnewswire.com published the news titled: “ContraVir Pharmaceuticals Appoints Thomas H. Adams, Ph.D., to Board of Directors” on September 21, 2016. Prnewswire.com‘s news article titled: “ContraVir Completes Merger with Ciclofilin Pharmaceuticals” with publication date: June 13, 2016 was also an interesting one.
CTRV Company Profile
ContraVir Pharmaceuticals, Inc., incorporated on May 15, 2013, is a biopharmaceutical company. The Firm focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Firm develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Firm is also developing an antiviral asset, FV-100.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.